Teva (TEVA) and Barr (BRL) Receive FTC Second Request Regarding Pending Acqusition
More News related to BRL
- FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream
- Barr Confirms Patent Challenge of Amrix(R) Extended-Release Capsules, 15mg & 30mg
- Cephalon (CEPH) and Eurand (EURX) File Infringement Suit Against Mylan (MYL) and Barr Pharma (BRL)
- Watson Pharmaceuticals (WPI) Agrees to Acquire Portfolio of Generic Pharma Products Following Teva/Barr Merger
- Barr (BRL) Shareholders Approval Proposed Acquisition of Teva (TEVA)
More News related to TEVA
- AstraZeneca (AZN) Settles Infringement Suit with Teva (TEVA) Subsidiary; Confirms FY09 EPS Outlook
- Teva Pharmaceuticals USA (TEVA) Signs Agreement to Settle Patent Litigation with AstraZeneca (AZN)
- Teva Announces Agreement on Generic Pulmicort Respules(R) Patent Challenge
- Watson Pharmaceuticals (WPI) Agrees to Acquire Portfolio of Generic Pharma Products Following Teva/Barr Merger
- Barr (BRL) Shareholders Approval Proposed Acquisition of Teva (TEVA)
More News related to Corporate News
- Friedman Billings Starts Aircastle (AYR) at Underperform
- Friedman Billings Starts Netflix (NFLX) at Market Perform
- Credit Suisse Starts 3PAR (PAR) at Neutral
- Credit Suisse Starts Netezza (NZ) at Neutral
- FBR Starts Amazon.com (AMZN) at Market Perform
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Barr Pharmaceuticals, Inc. (NYSE: BRL) announced today that, as expected, each party has received a second request from the U.S. FTC in connection with Teva's pending acquisition of Barr.
The effect of the second request is to extend the Hart-Scott-Rodino Antitrust Improvements Act of 1976 waiting period until thirty days after the parties have substantially complied with the request, unless that period is terminated sooner by the FTC. The companies continue to expect that the transaction will close in late 2008
Teva Pharmaceutical Industries Limited develops, manufactures, and markets generic and human pharmaceuticals, as well as active pharmaceutical ingredients (APIs) in North America, Europe, Latin America, Asia, and Israel.
Barr Pharmaceuticals, Inc. engages in the development, manufacture, and marketing of generic and proprietary pharmaceuticals.
Related Categories
Corporate NewsMergers and Acquisitions
Stocks Mentioned
-2.55Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
